Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83


TRAIL acts synergistically with iron oxide nanocluster-mediated magneto- and photothermia.

Belkahla H, Mazarío E, Sangnier AP, Lomas JS, Gharbi T, Ammar S, Micheau O, Wilhelm C, Hémadi M.

Theranostics. 2019 Aug 14;9(20):5924-5936. doi: 10.7150/thno.36320. eCollection 2019.


Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy.

Elmallah MIY, Micheau O.

Cancers (Basel). 2019 Jun 19;11(6). pii: E850. doi: 10.3390/cancers11060850. Review.


Generation and characterization of novel anti-DR4 and anti-DR5 antibodies developed by genetic immunization.

Dubuisson A, Favreau C, Fourmaux E, Lareure S, Rodrigues-Saraiva R, Pellat-Deceunynck C, El Alaoui S, Micheau O.

Cell Death Dis. 2019 Feb 4;10(2):101. doi: 10.1038/s41419-019-1343-5.


Release of c-FLIP brake selectively sensitizes human cancer cells to TLR3-mediated apoptosis.

Alkurdi L, Virard F, Vanbervliet B, Weber K, Toscano F, Bonnin M, Le Stang N, Lantuejoul S, Micheau O, Renno T, Lebecque S, Estornes Y.

Cell Death Dis. 2018 Aug 29;9(9):874. doi: 10.1038/s41419-018-0850-0.


Correction: DNA damage and S phase-dependent E2F1 stabilization requires the cIAP1 E3-ubiquitin ligase and is associated with K63-poly-ubiquitination on lysine 161/164 residues.

Glorian V, Allègre J, Berthelet J, Dumetier B, Boutanquoi PM, Droin N, Kayaci C, Cartier J, Gemble S, Marcion G, Gonzalez D, Boidot R, Garrido C, Micheau O, Solary E, Dubrez L.

Cell Death Dis. 2018 Jul 16;9(8):785. doi: 10.1038/s41419-018-0822-4.


The Ectodysplasin receptor EDAR acts as a tumor suppressor in melanoma by conditionally inducing cell death.

Vial J, Royet A, Cassier P, Tortereau A, Dinvaut S, Maillet D, Gratadou-Hupon L, Creveaux M, Sadier A, Tondeur G, Léon S, Depaepe L, Pantalacci S, de la Fouchardière A, Micheau O, Dalle S, Laudet V, Mehlen P, Castets M.

Cell Death Differ. 2019 Mar;26(3):443-454. doi: 10.1038/s41418-018-0128-1. Epub 2018 May 31.


Relationship between the agonist activity of synthetic ligands of TRAIL-R2 and their cell surface binding modes.

Chekkat N, Lombardo CM, Seguin C, Lechner MC, Dufour F, Nominé Y, De Giorgi M, Frisch B, Micheau O, Guichard G, Altschuh D, Fournel S.

Oncotarget. 2018 Feb 17;9(21):15566-15578. doi: 10.18632/oncotarget.24526. eCollection 2018 Mar 20.


Regulation of TNF-Related Apoptosis-Inducing Ligand Signaling by Glycosylation.

Micheau O.

Int J Mol Sci. 2018 Mar 2;19(3). pii: E715. doi: 10.3390/ijms19030715. Review.


Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy.

Dubuisson A, Micheau O.

Antibodies (Basel). 2017 Oct 25;6(4). pii: E16. doi: 10.3390/antib6040016. Review.


TRAIL-NP hybrids for cancer therapy: a review.

Belkahla H, Herlem G, Picaud F, Gharbi T, Hémadi M, Ammar S, Micheau O.

Nanoscale. 2017 May 11;9(18):5755-5768. doi: 10.1039/c7nr01469d. Review.


Marine actinomycete crude extracts with potent TRAIL-resistance overcoming activity against breast cancer cells.

Elmallah MIY, Micheau O, Eid MAG, Hebishy AMS, Abdelfattah MS.

Oncol Rep. 2017 Jun;37(6):3635-3642. doi: 10.3892/or.2017.5595. Epub 2017 Apr 21.


N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death.

Dufour F, Rattier T, Shirley S, Picarda G, Constantinescu AA, Morlé A, Zakaria AB, Marcion G, Causse S, Szegezdi E, Zajonc DM, Seigneuric R, Guichard G, Gharbi T, Picaud F, Herlem G, Garrido C, Schneider P, Benedict CA, Micheau O.

Cell Death Differ. 2017 Mar;24(3):500-510. doi: 10.1038/cdd.2016.150. Epub 2017 Feb 10.


Immunoprecipitation of Death Inducing Signaling Complex by Caspase-8.

Constantinescu AA, Morlé A, Micheau O.

Methods Mol Biol. 2017;1557:19-31. doi: 10.1007/978-1-4939-6780-3_3. Erratum in: Methods Mol Biol. 2017;1557:E1.


TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress.

Dufour F, Rattier T, Constantinescu AA, Zischler L, Morlé A, Ben Mabrouk H, Humblin E, Jacquemin G, Szegezdi E, Delacote F, Marrakchi N, Guichard G, Pellat-Deceunynck C, Vacher P, Legembre P, Garrido C, Micheau O.

Oncotarget. 2017 Feb 7;8(6):9974-9985. doi: 10.18632/oncotarget.14285.


The mycotoxin zearalenone enhances cell proliferation, colony formation and promotes cell migration in the human colon carcinoma cell line HCT116.

Abassi H, Ayed-Boussema I, Shirley S, Abid S, Bacha H, Micheau O.

Toxicol Lett. 2016 Jul 8;254:1-7. doi: 10.1016/j.toxlet.2016.04.012. Epub 2016 Apr 12.


Enhanced DR5 binding capacity of nanovectorized TRAIL compared to its cytotoxic version by affinity chromatography and molecular docking studies.

Zakaria A, Picaud F, Guillaume YC, Gharbi T, Micheau O, Herlem G.

J Mol Recognit. 2016 Sep;29(9):406-14. doi: 10.1002/jmr.2539. Epub 2016 Mar 7.


CC5 and CC8, two homologous disintegrins from Cerastes cerastes venom, inhibit in vitro and ex vivo angiogenesis.

Ben-Mabrouk H, Zouari-Kessentini R, Montassar F, Koubaa ZA, Messaadi E, Guillonneau X, ElAyeb M, Srairi-Abid N, Luis J, Micheau O, Marrakchi N.

Int J Biol Macromol. 2016 May;86:670-80. doi: 10.1016/j.ijbiomac.2016.02.008. Epub 2016 Feb 4.


Chemotherapy with ceramide in TNBC.

Legembre P, Micheau O, Ségui B.

Oncoscience. 2015 Aug 21;2(10):817-8. eCollection 2015. No abstract available.


Marine Drugs Regulating Apoptosis Induced by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL).

Elmallah MI, Micheau O.

Mar Drugs. 2015 Nov 13;13(11):6884-909. doi: 10.3390/md13116884. Review.


Correction to "Nanovectorization of TRAIL with Single Wall Carbon Nanotubes Enhances Tumor Cell Killing".

Zakaria AB, Picaud F, Rattier T, Pudlo M, Dufour F, Saviot L, Chassagnon R, Lherminier J, Gharbi T, Micheau O, Herlem G.

Nano Lett. 2015 Aug 12;15(8):5664. doi: 10.1021/acs.nanolett.5b02056. Epub 2015 Jun 12. No abstract available.


Death Receptor-Induced Apoptosis Signalling Regulation by Ezrin Is Cell Type Dependent and Occurs in a DISC-Independent Manner in Colon Cancer Cells.

Iessi E, Zischler L, Etringer A, Bergeret M, Morlé A, Jacquemin G, Morizot A, Shirley S, Lalaoui N, Elifio-Esposito SL, Fais S, Garrido C, Solary E, Micheau O.

PLoS One. 2015 May 26;10(5):e0126526. doi: 10.1371/journal.pone.0126526. eCollection 2015.


Hyperthermia restores apoptosis induced by death receptors through aggregation-induced c-FLIP cytosolic depletion.

Morlé A, Garrido C, Micheau O.

Cell Death Dis. 2015 Feb 12;6:e1633. doi: 10.1038/cddis.2015.12.


Nanovectorization of TRAIL with single wall carbon nanotubes enhances tumor cell killing.

Zakaria AB, Picaud F, Rattier T, Pudlo M, Dufour F, Saviot L, Chassagnon R, Lherminier J, Gharbi T, Micheau O, Herlem G.

Nano Lett. 2015 Feb 11;15(2):891-5. doi: 10.1021/nl503565t. Epub 2015 Jan 14. Erratum in: Nano Lett. 2015 Aug 12;15(8):5664. Dufour, Florent [Added].


Sphingolipids modulate the epithelial-mesenchymal transition in cancer.

Levade T, Andrieu-Abadie N, Micheau O, Legembre P, Ségui B.

Cell Death Discov. 2015 Oct 12;1:15001. doi: 10.1038/cddiscovery.2015.1. eCollection 2015. No abstract available.


Downregulation of ceramide synthase-6 during epithelial-to-mesenchymal transition reduces plasma membrane fluidity and cancer cell motility.

Edmond V, Dufour F, Poiroux G, Shoji K, Malleter M, Fouqué A, Tauzin S, Rimokh R, Sergent O, Penna A, Dupuy A, Levade T, Theret N, Micheau O, Ségui B, Legembre P.

Oncogene. 2015 Feb 19;34(8):996-1005. doi: 10.1038/onc.2014.55. Epub 2014 Mar 17.


Regulation of the proapoptotic functions of prostate apoptosis response-4 (Par-4) by casein kinase 2 in prostate cancer cells.

de Thonel A, Hazoumé A, Kochin V, Isoniemi K, Jego G, Fourmaux E, Hammann A, Mjahed H, Filhol O, Micheau O, Rocchi P, Mezger V, Eriksson JE, Rangnekar VM, Garrido C.

Cell Death Dis. 2014 Jan 23;5:e1016. doi: 10.1038/cddis.2013.532.


Death receptors as targets in cancer.

Micheau O, Shirley S, Dufour F.

Br J Pharmacol. 2013 Aug;169(8):1723-44. doi: 10.1111/bph.12238. Review.


Inhibition of HSP27 blocks fibrosis development and EMT features by promoting Snail degradation.

Wettstein G, Bellaye PS, Kolb M, Hammann A, Crestani B, Soler P, Marchal-Somme J, Hazoume A, Gauldie J, Gunther A, Micheau O, Gleave M, Camus P, Garrido C, Bonniaud P.

FASEB J. 2013 Apr;27(4):1549-60. doi: 10.1096/fj.12-220053. Epub 2013 Jan 3.


TRAIL promotes membrane blebbing, detachment and migration of cells displaying a dysfunctional intrinsic pathway of apoptosis.

Somasekharan SP, Koc M, Morizot A, Micheau O, Sorensen PH, Gaide O, Andera L, Martinou JC.

Apoptosis. 2013 Mar;18(3):324-36. doi: 10.1007/s10495-012-0782-6.


Small heat shock proteins and the cytoskeleton: an essential interplay for cell integrity?

Wettstein G, Bellaye PS, Micheau O, Bonniaud P.

Int J Biochem Cell Biol. 2012 Oct;44(10):1680-6. doi: 10.1016/j.biocel.2012.05.024. Epub 2012 Jun 7. Review.


dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8.

Estornes Y, Toscano F, Virard F, Jacquemin G, Pierrot A, Vanbervliet B, Bonnin M, Lalaoui N, Mercier-Gouy P, Pachéco Y, Salaun B, Renno T, Micheau O, Lebecque S.

Cell Death Differ. 2012 Sep;19(9):1482-94. doi: 10.1038/cdd.2012.22. Epub 2012 Mar 16.


Thiocolchicoside a semi-synthetic derivative of the Glory Lily: a new weapon to fight metastatic bone resorption?

Micheau O, Dufour F, Walczak H.

Br J Pharmacol. 2012 Apr;165(7):2124-6. doi: 10.1111/j.1476-5381.2011.01792.x.


Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells.

Jacquemin G, Granci V, Gallouet AS, Lalaoui N, Morlé A, Iessi E, Morizot A, Garrido C, Guillaudeux T, Micheau O.

Haematologica. 2012 Jan;97(1):38-46. doi: 10.3324/haematol.2011.046466. Epub 2011 Sep 20.


Identification of a novel pro-apoptotic role of NF-κB in the regulation of TRAIL- and CD95-mediated apoptosis of glioblastoma cells.

Jennewein C, Karl S, Baumann B, Micheau O, Debatin KM, Fulda S.

Oncogene. 2012 Mar 15;31(11):1468-74. doi: 10.1038/onc.2011.333. Epub 2011 Aug 8.


Regulating TRAIL receptor-induced cell death at the membrane : a deadly discussion.

Shirley S, Morizot A, Micheau O.

Recent Pat Anticancer Drug Discov. 2011 Sep;6(3):311-23. doi: 10.2174/157489211796957757. Review.


Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.

El Fajoui Z, Toscano F, Jacquemin G, Abello J, Scoazec JY, Micheau O, Saurin JC.

Gastroenterology. 2011 Aug;141(2):663-73. doi: 10.1053/j.gastro.2011.04.055. Epub 2011 Apr 30.


TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKT.

Lalaoui N, Morlé A, Mérino D, Jacquemin G, Iessi E, Morizot A, Shirley S, Robert B, Solary E, Garrido C, Micheau O.

PLoS One. 2011;6(5):e19679. doi: 10.1371/journal.pone.0019679. Epub 2011 May 20.


Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy.

Rérole AL, Gobbo J, De Thonel A, Schmitt E, Pais de Barros JP, Hammann A, Lanneau D, Fourmaux E, Demidov ON, Micheau O, Lagrost L, Colas P, Kroemer G, Garrido C.

Cancer Res. 2011 Jan 15;71(2):484-95. doi: 10.1158/0008-5472.CAN-10-1443. Epub 2011 Jan 11. Erratum in: Cancer Res. 2015 Mar 1;75(5):902. Deminov, Oleg [corrected to Demidov, Oleg N].


Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level.

Morizot A, Mérino D, Lalaoui N, Jacquemin G, Granci V, Iessi E, Lanneau D, Bouyer F, Solary E, Chauffert B, Saas P, Garrido C, Micheau O.

Cell Death Differ. 2011 Apr;18(4):700-11. doi: 10.1038/cdd.2010.144. Epub 2010 Nov 12.


Targeting c-FLIP in cancer.

Shirley S, Micheau O.

Cancer Lett. 2013 May 28;332(2):141-50. doi: 10.1016/j.canlet.2010.10.009. Epub 2010 Nov 10. Review.


Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells?

Jacquemin G, Shirley S, Micheau O.

Cell Mol Life Sci. 2010 Sep;67(18):3115-30. doi: 10.1007/s00018-010-0407-6. Epub 2010 May 29. Review.


Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity.

Pavet V, Beyrath J, Pardin C, Morizot A, Lechner MC, Briand JP, Wendland M, Maison W, Fournel S, Micheau O, Guichard G, Gronemeyer H.

Cancer Res. 2010 Feb 1;70(3):1101-10. doi: 10.1158/0008-5472.CAN-09-2889. Epub 2010 Jan 26.


Peroxynitrite-dependent killing of cancer cells and presentation of released tumor antigens by activated dendritic cells.

Fraszczak J, Trad M, Janikashvili N, Cathelin D, Lakomy D, Granci V, Morizot A, Audia S, Micheau O, Lagrost L, Katsanis E, Solary E, Larmonier N, Bonnotte B.

J Immunol. 2010 Feb 15;184(4):1876-84. doi: 10.4049/jimmunol.0900831. Epub 2010 Jan 20.


Colony-stimulating factor-1-induced oscillations in phosphatidylinositol-3 kinase/AKT are required for caspase activation in monocytes undergoing differentiation into macrophages.

Jacquel A, Benikhlef N, Paggetti J, Lalaoui N, Guery L, Dufour EK, Ciudad M, Racoeur C, Micheau O, Delva L, Droin N, Solary E.

Blood. 2009 Oct 22;114(17):3633-41. doi: 10.1182/blood-2009-03-208843. Epub 2009 Aug 31.


Molecular crosstalk between TRAIL and natural antioxidants in the treatment of cancer.

Rushworth SA, Micheau O.

Br J Pharmacol. 2009 Aug;157(7):1186-8. doi: 10.1111/j.1476-5381.2009.00266.x.


Distinct requirements for activation-induced cell surface expression of preformed Fas/CD95 ligand and cytolytic granule markers in T cells.

Kassahn D, Nachbur U, Conus S, Micheau O, Schneider P, Simon HU, Brunner T.

Cell Death Differ. 2009 Jan;16(1):115-24. doi: 10.1038/cdd.2008.133. Epub 2008 Sep 12.


CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NF-kappaB activation and up-regulation of c-FLIP and Bcl-xL.

Travert M, Ame-Thomas P, Pangault C, Morizot A, Micheau O, Semana G, Lamy T, Fest T, Tarte K, Guillaudeux T.

J Immunol. 2008 Jul 15;181(2):1001-11.


A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma.

Ndozangue-Touriguine O, Sebbagh M, Mérino D, Micheau O, Bertoglio J, Bréard J.

Oncogene. 2008 Oct 9;27(46):6012-22. doi: 10.1038/onc.2008.197. Epub 2008 Jun 16.


P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.

Toscano F, Fajoui ZE, Gay F, Lalaoui N, Parmentier B, Chayvialle JA, Scoazec JY, Micheau O, Abello J, Saurin JC.

Oncogene. 2008 Jul 10;27(30):4161-71. doi: 10.1038/onc.2008.52. Epub 2008 Mar 17.


Supplemental Content

Loading ...
Support Center